Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab biosimilar - Celltrion

Next Previous
Drug Profile

Pembrolizumab biosimilar - Celltrion

Alternative Names: CT P51

Latest Information Update: 30 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celltrion
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Malignant melanoma

Most Recent Events

  • 30 Jan 2025 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease, Late-stage disease) in Georgia (Parenteral) (NCT06939595)
  • 30 Dec 2024 Celltrion plans a phase III trial for Non-squamous non-small cell lung cancer (Metastatic disease, First line therapy) (Parenteral) (EUCT2024-514048-98-00) (Celltrion pipeline, December 2024)
  • 23 Aug 2024 Phase-I clinical trials in Malignant melanoma (Adjuvant therapy, Late-stage disease) in Albania, Brazil, Croatia, Italy, Moldova, Poland, Peru, Romania, Serbia, Slovenia, Slovenia, Spain, Spain, Turkey, Ukraine, South Africa, Georgia (Parenteral) (CTIS2023-510017-26-00) (EudraCT-2023-510017-26-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top